Brief: Annexin Resolves Rights Issue Of About SEK 20 Mln
04/06/2026 07:07
BRIEF-Annexin Resolves Rights Issue Of About SEK 20 Mln June 4(Reuters) - Annexin Pharmaceuticals AB (publ) ANNX.ST:
SAID ON WEDNESDAY CO RESOLVES RIGHTS ISSUE OF ABOUT SEK 20 MLN
SUBSCRIPTION PRICE AMOUNTS TO SEK 12 PER NEW SHARE
IF OVERSUBSCRIBED, BOD MAY RESOLVE TO INCREASE TOTAL ISSUE AMOUNT BY UP TO ABOUT SEK 5 MLN THROUGH OVERALLOTMENT OPTION
Source text for Workspace: nMFN65PpHl
Further company coverage: ANNX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Annexin Pharmaceuticals AB (publ)
See all newsBrief: Annexin Resolves Rights Issue Of About SEK 20 Mln
Brief: Annexin Receives German Approval For ANXV Clinical Trial
Brief: Annexin Secures Financing Through Bridge Loan Facility, Plans Rights Issue
Brief: Annexin Pharmaceuticals Q4 Net Loss At SEK 10.5 Mln
Brief: Annexin Gets Approval For Phase 2A Study In Diabetic Retinopathy, RVO